Citations

Showing 10 of 108119 citations.

PRN OPINION PAPER: Application of precision medicine across pharmacy specialty areas
Caudle, Kelly E. , Gammal, Roseann S., Karnes, Jason H. , Afanasjeva, Janna, Anderson, Keri C. , Frazee, Erin N. , Beavers, C. , Bhat, Shubha , Birrer, Kara L., Ensor, Christopher R. , Flowers, Stephanie A. , Formea, Christine M. , George, Jomy, Gosser, Rena , Karaoui, Lamis R. , Kolpek, Jimmi Hatton , Leung, Jonathan G. , Maldonado, Angela Q. , Minze, Molly G. , Pulk, Rebecca , Shelton, Chasity M. , Sheridan, Maria , Smith, Michael A. , Soefje, Scott A. , Tellez‐Corrales, Eglis , Walko, Christine M. , Leung, Jonathan G , Soefje, Scott A , Chahine, Elias B. , Hébert, Mary F. , Lee, James C. , Sheridan, Maria, Cavallari, Larisa H.

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | March 25, 2019 | Volume: 2 | Issue: 3 | Pages: 288-302

10.1002/jac5.1107 Get It

Clinical pharmacists have been incorporating precision medicine into practice for decades. Drug selection and dosing based on patient‐specific clinical factors such as age, weight, renal function, drug interactions, plasma drug concentrations, and diet are expected as part of routine clinical practice. Newer concepts of precision medicine such as pharmacogenomics have recently been implemented into clinical care, while other concepts such as epigenetics and pharmacomicrobiomics still predominantly exist in the research area but clinical translation is expected in the future. The purpose of this paper is to describe current and emerging aspects of precision medicine as it relates to clinical pharmacy across a variety of specialty areas of practice, with perspectives from the American College of Clinical Pharmacy Practice and Research Network membership.
Outcomes of Adjuvant Radiotherapy Following Negative Surgical Margins for Cutaneous Squamous Cell Carcinoma
Chang, Timothy W., Peters, Margot S. , Baum, Christian L. , Peters, Margot, Miller, Jonathan M. , Schwartz, David Asa

Mayo Clinic

Dermatologic Surgery | March 24, 2019 | Volume: 45 | Issue: 9 | Pages: 1111-1116

10.1097/dss.0000000000001827 | PMID 30893176 Get It

BACKGROUND The role of adjuvant radiotherapy (ART) for cutaneous squamous cell carcinoma (cSCC) following negative surgical margins is unclear. OBJECTIVE To retrospectively examine the clinical outcomes in a cohort of patients with cSCC who completed ART after Mohs micrographic surgery or wide local excision with negative margins. METHODS AND MATERIALS After the institutional review board approval, a retrospective review was conducted of all patients with cSCC treated in the Mayo Clinic Department of Radiation Oncology from March 10, 1998, through April 26, 2013. Inclusion criteria were age >18 years, resection with negative histologic surgical margins, and completion of ART. RESULTS Thirty-two patients met the inclusion criteria: 15 patients died, 12 without evidence of disease related to cSCC. Three patients developed recurrent disease, all with poorly differentiated cSCC, > 2 cm in clinical diameter, perineural invasion, and Brigham and Women's (BWH) stage T2b/T3; 2 of 3 patients were immunosuppressed; and 2 of 3 patients died of cSCC-related causes. CONCLUSION These data suggest that the combination of surgical resection and ART is a reasonable option for Brigham and Women's T2b/T3 tumors.
Postoperative Hardware-Related Infection from Kytococcus schroeteri: Its Association with Prosthetic Material and Hematological Malignancies—A Report of a Case and Review of Existing Literature
Shah, Aditya , Vijayvargiya, Prakhar , Jung, Sarah , Wilson, John , Shah, Aditya S

Mayo Clinic

Case Reports in Infectious Diseases | March 24, 2019 | Volume: 2019 | Issue: No issue available | Pages: 1-4

10.1155/2019/6936472 | PMID 31019817 Get It

Introduction. Kytococcus schroeteri is an infrequently isolated Gram-positive coccus often encountered as a commensal bacterium. Only eighteen cases of human infection associated with this organism have been previously reported. Most of these cases involved patients with implanted prosthetic materials or patients with immunosuppressive conditions. It has been described in prosthetic valve endocarditis and in select patients with hematologic diseases but only one prior report as being involved in osteoarticular infections. Case Presentation. We describe a case of postsurgical osteoarticular hardware-related infection by K. schroeteri and discuss a possible association with implanted prosthetic material. Conclusion. Other clinical presentations of K. schroeteri, including reported infection syndromes, antimicrobial susceptibility profiles, and treatment outcomes, are also reviewed.
Reply to: ‘Effects of aspirin and non-steroidal anti-inflammatory drugs on the risk of cholangiocarcinoma: a meta-analysis’
Lapumnuaypol, Kamolyut , Tiu, Andrew , Thongprayoon, Charat , Wijarnpreecha, Karn , Ungprasert, Patompong , Cheungpasitporn, Wisit , Cheungpasitporn, Wisit , Thongprayoon, Charat , Wijarnpreecha, Karn , Mao, Michael A.

Mayo Clinic

QJM: An International Journal of Medicine | March 24, 2019 | Volume: 112 | Issue: 8 | Pages: 645-645

10.1093/qjmed/hcz075 | PMID 30907969 Get It

Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline
LeRoith, Derek, Biessels, Geert Jan , Braithwaite, Susan S., Draznin, Boris , Halter, Jeffrey B., McDonnell, Marie E. , Molitch, Mark E. , Murad, M. Hassan , Murad, M Hassan , McDonnell, Marie E , Biessels, Geert Jan , Casanueva, Felipe F. , Hirsch, Irl B. , Sinclair, Alan J.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | March 23, 2019 | Volume: 104 | Issue: 5 | Pages: 1520-1574

10.1210/jc.2019-00198 | PMID 30903688 Get It

Abstract Objective The objective is to formulate clinical practice guidelines for the treatment of diabetes in older adults. Conclusions Diabetes, particularly type 2, is becoming more prevalent in the general population, especially in individuals over the age of 65 years. The underlying pathophysiology of the disease in these patients is exacerbated by the direct effects of aging on metabolic regulation. Similarly, aging effects interact with diabetes to accelerate the progression of many common diabetes complications. Each section in this guideline covers all aspects of the etiology and available evidence, primarily from controlled trials, on therapeutic options and outcomes in this population. The goal is to give guidance to practicing health care providers that will benefit patients with diabetes (both type 1 and type 2), paying particular attention to avoiding unnecessary and/or harmful adverse effects.
Lipid-Lowering Agents in Older Individuals: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Ponce, Oscar J. , Larrea-Mantilla, Laura , Hemmingsen, Bianca , Serrano, Valentina, Rodríguez‐Gutiérrez, René , Spencer‐Bonilla, Gabriela , Álvarez‐Villalobos, Neri Alejandro , Benkhadra, Khaled, Haddad, Abdullah , Brito, Juan P. , Murad, M. Hassan , Alvarez-Villalobos, Neri, Murad, Mohammad Hassan, Murad, M Hassan , Álvarez-Villalobos, Neri A , Brito, Juan P , Ponce, Oscar Josue , Gionfriddo, Michael R. , Prokop, Larry J.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | March 23, 2019 | Volume: 104 | Issue: 5 | Pages: 1585-1594

10.1210/jc.2019-00195 | PMID 30903687 Get It

Abstract Background The efficacy of lipid-lowering agents on patient-important outcomes in older individuals is unclear. Methods We included randomized trials that enrolled individuals aged 65 years or older and that included at least 1 year of follow-up. Pairs of reviewers selected and appraised the trials. Results We included 23 trials that enrolled 60,194 elderly patients. For primary prevention, statins reduced the risk of coronary artery disease [CAD; relative risk (RR): 0.79, 95% CI: 0.68 to 0.91] and myocardial infarction (MI; RR: 0.45, 95% CI: 0.31 to 0.66) but not all-cause or cardiovascular mortality or stroke. These effects were imprecise in patients with diabetes, but there was no significant interaction between diabetes status and the intervention effect. For secondary prevention, statins reduced all-cause mortality (RR: 0.80, 95% CI: 0.73 to 0.89), cardiovascular mortality (RR: 0.68, 95% CI: 0.58 to 0.79), CAD (RR: 0.68, 95% CI: 0.61 to 0.77), MI (RR: 0.68, 95% CI: 0.59 to 0.79), and revascularization (RR: 0.68, 95% CI: 0.61 to 0.77). Intensive (vs less-intensive) statin therapy reduced the risk of CAD and heart failure. Niacin did not reduce the risk of revascularization, and fibrates did not reduce the risk of stroke, cardiovascular mortality, or CAD. Conclusion High-certainty evidence supports statin use for secondary prevention in older individuals. Evidence for primary prevention is less certain. Data in older individuals with diabetes are limited; however, no empirical evidence has shown a significant difference based on diabetes status.
Surgical Outcomes of Prepectoral Versus Subpectoral Implant-based Breast Reconstruction in Young Women
Manrique, Oscar J. , Banuelos, Joseph, Nguyen, Minh-Doan T., Tran, Nho V. , Martinez‐Jorge, Jorys, Harless, Christin A., Sharaf, Basel , Jakub, James W. , Jacobson, Steven R., Abu-Ghname, Amjed, Nguyen, Minh-Doan, Martinez-Jorge, Jorys, Harless, Christin, Jakub, James W , Abu‐Ghname, Amjed , Nguyen, Minh-Doan T. , Degnim, Amy C. , Boughey, Judy C. , Sharaf, Basel A

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | March 22, 2019 | Volume: 7 | Issue: 3 | Pages: e2119

10.1097/gox.0000000000002119 | PMID 31044105 Get It

Background: Two-staged implant-based reconstruction (IBR) is the most common breast reconstructive modality. Recently, technological and surgical advances have encouraged surgeons to revisit prepectoral IBR. Data comparing prepectoral against subpectoral IBR in women under the age of 40 are lacking. Methods: Retrospective chart review of patients under the age of 40 years old, who underwent immediate 2-staged IBR at our institution, was performed. Patient’s demographics, clinical characteristics, operative details, and early surgical outcomes of prepectoral and subpectoral reconstruction were compared. Data with values of P < 0.05 were considered statistically significant. Results: Between 2012 and 2016, 100 patients (187 breasts) who underwent prepectoral and 69 patients (124 breasts) who underwent subpectoral IBR were included. Median follow-up was 17.9 and 17.5 months in the prepectoral and subpectoral groups, respectively. Total number of complications including both stages of reconstruction was 20 (10.7%) and 19 (15.3%) in the prepectoral and subpectoral groups, respectively (P = 0.227). Specific complications, including hematoma, seroma, skin flap necrosis, wound dehiscence, and breast infections, were not significantly different among groups. Ten (5.4%) devices, including implants and tissue expander, required explantation in the prepectoral group and 8 (6.5%) in the subpectoral group (P = 0.683). Explantation was most commonly due to infection (n = 14), and all of them occurred during the first stage (P < 0.001). Conclusions: Early complications and implant explantation rates are comparable among prepectoral and subpectoral breast reconstruction in women under 40 years old. Based on these results, we believe that prepectoral IBR is a safe, reliable, and promising reconstructive option.
Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma
DiNorcia, Joseph , Haydel, Brandy , Tabrizian, Parissa , Ruiz, Richard , Klintmalm, Göran B. , Senguttuvan, Srinath, Lee, David D. , Verna, Elizabeth C. , Halazun, Karim J. , Chapman, William C. , Vachharajani, Neeta , Aucejo, Federico , Nguyen, Mindie H. , Melcher, Marc L. , Tevar, Amit D. , Humar, Abhinav , Mobley, Constance M. , Ghobrial, R. Mark , Nydam, Trevor L. , Amundsen, Beth, Markmann, James F. , Berumen, Jennifer , Hemming, Alan W. , Langnas, Alan N. , Carney, Carol A., Sudan, Debra L. , Hong, Johnny C. , Kim, Joohyun , Zimmerman, Michael A. , Rana, Abbas , Kueht, Michael , Jones, Christopher M. , Fishbein, Thomas , Markovic, Daniela , Busuttil, Ronald W. , Taner, C. Burcin , Lee, David D , Melcher, Marc L , Halazun, Karim J , Chapman, William C , Sudan, Debra L , Florman, Sander , Hoteit, Maarouf , Levine, Matthew H , Agopian, Vatche G.

Mayo Clinic

Annals of Surgery | March 22, 2019 | Volume: 271 | Issue: 4 | Pages: 616-624

10.1097/sla.0000000000003253 | PMID 30870180 Get It

Objective: The aim of the study was to determine the rate, predictors, and impact of complete pathologic response (cPR) to pretransplant locoregional therapy (LRT) in a large, multicenter cohort of hepatocellular carcinoma (HCC) patients undergoing liver transplantation (LT). Background: LRT is used to mitigate waitlist dropout for patients with HCC awaiting LT. Degree of tumor necrosis found on explant has been associated with recurrence and overall survival, but has not been evaluated in a large, multicenter study. Methods: Comparisons were made among patients receiving pre-LT LRT with (n = 802) and without (n = 2637) cPR from the United States Multicenter HCC Transplant Consortium (UMHTC), and multivariable predictors of cPR were identified using logistic regression. Results: Of 3439 patients, 802 (23%) had cPR on explant. Compared with patients without cPR, cPR patients were younger; had lower Model for End-stage Liver Disease (MELD) scores, AFP levels, and neutrophil–lymphocyte ratios (NLR); were more likely to have tumors within Milan criteria and fewer LRT treatments; and had significantly lower 1-, 3-, and 5-year incidence of post-LT recurrence (1.3%, 3.5%, and 5.2% vs 6.2%, 13.5%, and 16.4%; P < 0.001) and superior overall survival (92%, 84%, and 75% vs 90%, 78%, and 68%; P < 0.001). Multivariable predictors of cPR included age, sex, liver disease diagnosis, MELD, AFP, NLR, radiographic Milan status, and number of LRT treatments (C-statistic 0.67). Conclusions: For LT recipients with HCC receiving pretransplant LRT, achieving cPR portends significantly lower posttransplant recurrence and superior survival. Factors predicting cPR are identified, which may help prioritize patients and guide LRT strategies to optimize posttransplant cancer outcomes.